A Top 10 Emerging Pharma Watch List
By

By
Emerging pharma companies play an important role in new product development. Which companies are making strong plays based on recent high-value partnering deals? DCAT Value Chain Insights’ Top 10 highlights…

Pharma Company on the Move: The New AbbVie
By

By
Following AbbVie’s $63-billion acquisition of Allergan, which closed earlier this month (May 2020), the new AbbVie, reflecting the combined companies, has projected revenues of $50 billion. DCAT Value Chain Insights…

FDA Issues Guidance for Competitive Generic Therapies
By

By
As part of its Drug Competition Action Plan, the FDA has finalized guidance to outline a new regulatory pathway for “competitive generic therapies” (CGTs). What are CGTs, and how is…

Orphan Drugs: Bearing Revenue Gains or Not?
By

By
Orphan drugs, defined in the US as a drug to treat less than 200,000 patients, have accounted for more than 40% of new drug approvals by the FDA over the…

Is Novartis on the Right Track?
By

By
With five new molecular entities launched in 2019 and two potential blockbusters targeted for launch in 2020, is the strategy of Novartis CEO Vas Narasimhan to drive growth in the…

2020 Vision: What is Impacting Global Supply Lines?
By

By
From a more pessimistic macroeconomic view, to uncertainty arising from ongoing trade conflicts, and geopolitical tensions, executives weigh in on key issues that will impact performance in 2020. Taking the…

Drug Shortages: How Should the Industry Address?
By

By
The European Federation of Pharmaceutical Industries and Associations (EFPIA), which represents research-based innovator companies, put out a position paper on how to best address drug shortages. This follows reports by…

A Top 10 Pharma Watch List for 2020
By

By
With 2020 underway, what are key developments and trends in the pharmaceutical industry that are on the industry’s radar for this year? DCAT Value Chain Insights provides its Top 10…

Emerging Biopharma Companies: Tracking Their Contribution to Innovation
By

By
Emerging biopharma companies are an important source of new product development, but to what extent are they contributing to the industry’s pipeline and new product growth? A recent analysis by…

CDMO/CMOs: The Top 10 Movers and Shakers of 2019
By

By
What was the most noteworthy activity from CDMOs/CMOs in 2019? DCAT Value Chain Insights’ Top 10 ranking reveals the companies involved in the most significant mergers and acquisitions and expansions…